Cervical disc replacement: examining “real-world” utilization of an emerging technology

Restricted access

OBJECTIVE

Cervical disc replacement (CDR) has emerged as an alternative to anterior cervical discectomy and fusion (ACDF) for the management of cervical spondylotic pathology. While much is known about the efficacy of CDR within the constraints of a well-controlled, experimental setting, little is known about general utilization. The authors present an analysis of temporal and geographic trends in “real-world” utilization of CDR among those enrolled in private insurance plans in the US.

METHODS

Eligible subjects were identified from the IBM MarketScan Databases between 2009 and 2017. Individuals 18 years and older, undergoing a single-level CDR or ACDF for cervical radiculopathy and/or myelopathy, were identified. US Census divisions were used to classify the region where surgery was performed. Two-level mixed-effects regression modeling was used to study regional differences in proportional utilization of CDR, while controlling for confounding by regional case-mix differences.

RESULTS

A total of 47,387 subjects met the inclusion criteria; 3553 underwent CDR and 43,834 underwent ACDF. At a national level, the utilization of single-level CDR rose from 5.6 cases for every 100 ACDFs performed in 2009 to 28.8 cases per 100 ACDFs in 2017. The most substantial increases occurred from 2013 onward. The region of highest utilization was the Mountain region (Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming), where 14.3 CDRs were performed for every 100 ACDFs (averaged over the 9-year period of study). This is in contrast to the East South Central region (Alabama, Kentucky, Mississippi, and Tennessee), where only 2.1 CDRs were performed for every 100 ACDFs. Patient factors that significantly increased the odds of undergoing a CDR were age younger than 40 years (OR 15.9 [95% CI 10.0–25.5]; p < 0.001), no clinical evidence of myelopathy/myeloradiculopathy (OR 1.5 [95% CI 1.4–1.7]; p < 0.001), and a Charlson Comorbidity Index score of 0 (OR 2.7 [95% CI 1.7–4.2]; p < 0.001). After controlling for these factors, significant differences in utilization rates remained between regions (chi-square test = 830.4; p < 0.001).

CONCLUSIONS

This US national level study lends insight into the rate of uptake and geographic differences in utilization of the single-level CDR procedure. Further study will be needed to ascertain specific factors that predict adoption of this technology to explain observed geographic discrepancies.

ABBREVIATIONS ACDF = anterior cervical discectomy and fusion; CDR = cervical disc replacement; CPT = Current Procedural Terminology; FDA = Food and Drug Administration.

Supplementary Materials

  • Supplementary Table 1 (PDF 413 KB)
Article Information

Contributor Notes

Correspondence Christopher D. Witiw: St. Michael’s Hospital, Toronto, ON, Canada. christopher.witiw@unityhealth.to.INCLUDE WHEN CITING Published online January 17, 2020; DOI: 10.3171/2019.10.SPINE19919.Disclosures Dr. Traynelis reports being a consultant for Medtronic and NuVasive; being a patent holder with Medtronic; and receiving clinical or research support for the present study from NREF.
Headings
TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 753 753 702
Full Text Views 89 89 79
PDF Downloads 55 55 52
EPUB Downloads 0 0 0
PubMed
Google Scholar